Latest news with #GlandPharma
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Gland Pharma stock volatile after announcing Q4 results, dividend; Details
Gland Pharma share price slipped 2 per cent in the morning deals, however, its losses reversed and the stock was trading 4.9 per cent higher on BSE. The volatility in the stock came after the company reported its Q4 results. At 9:55 AM, Gland Pharma shares were up 4.14 per cent at ₹1,558 per share on the BSE. In comparison, the BSE Sensex was up 0.66 per cent at 81,721.26. The market capitalisation of the company stood at ₹25,669.05 crore. The 52-week high of the stock was at ₹2,220.95 per share and the 52-week low of the stock was at ₹1,200 per share. Gland Pharma Q4 results 2025 The company announced its fourth quarter (Q4FY25) results on May 20, 2025, after market hours. The company's consolidated net profit after tax (PAT) stood at ₹186.5 crore as compared to ₹192.4crore a year ago, down 3 per cent year-on-year (Y-o-Y). Its revenue from operations also slipped 7 per cent at ₹1,424.9 crore for Q4 against ₹1,537.5 crore a year ago. Its Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹347.5 crore as compared to ₹358.7 crore a year ago. The Ebitda margin for the quarter came in at 24 per cent against 23 per cent Y-o-Y. According to the filing, research and development (R&D) expenses were ₹50.3 crore in Q4 FY25, representing 4.9 per cent of revenue, while for FY25 were ₹192.2 crore (4.7 per cent of revenue). The company launched four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), which were launched in Q4 FY25, contributing to 31 cumulative launches in FY25. In the quarter under review, five Abbreviated New Drug Application (ANDAs) were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the US (318 approved, 53 pending). Gland Pharma dividend The board of Gland Pharma recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. About Gland Pharma Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets.
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%
Shares of pharmaceutical companies were in demand, and rallied up to 8 per cent on the bourses in Wednesday's intra-day trade on healthy growth outlook. In-line March quarter performance, coupled with Torrent Pharma and Gland Pharma's optimistic FY26 guidance led the up move in pharma stocks. GlaxoSmithKline Pharmaceuticals (GSK Pharma), Ajanta Pharma, Gland Pharma, Jubilant Pharmova, Torrent Pharmaceuticals, Natco Pharma, Aurobindo Pharma, Lupin, Ipca Labs, Dr Reddy's Laboratories, Cipla, Divi's Laboratories, Granules India and Sun Pharmaceutical were up in the range of 2 per cent to 8 per cent in intra-day trade. At 09:52 AM; the Nifty Pharma, the top gainer among sectoral indices, was up 1.6 per cent, as compared to 0.56 per cent rise in the Nifty 50. The pharma index rallied 2.3 per cent in intra-day trade today. The Indian pharmaceutical market (IPM) reported growth of 7.4 per cent year-on-year (YoY) in April 2025 on a base of 9.5 per cent YoY growth in April 2024. IPM growth in Moving Annual Turnover (MAT) April 2025 stood at 7.9 per cent YoY versus 7.3 per cent YoY growth in MAT April 2024, with volumes contributing 130 bps, much higher than the nil contribution in MAT April 2024. India Ratings and Research (Ind-Ra), part of the Fitch Group, said the continued revenue growth was driven by companies' price hikes, with volume growing 1.3 per cent year-on-year (YoY). 'India Ratings expects IPM to grow 7-8 per cent YoY during the financial year 2025-26 (FY26) with sustained growth momentum in the chronic therapies, led by price increases and product launches', said Nishith Sanghvi, director, corporate ratings, India Ratings. Kotak Institutional Equities highlights that, although pricing contributed to the bulk of the growth, volume traction in the end-market still remains sluggish. However, the brokerage firm expects a slightly stronger acute season along with pricing, acquisitions and in-licensing deals to drive 10 per cent-23 per cent YoY growth in FY2026E domestic sales for its coverage. ALSO READ | Meanwhile, Ind-Ra opines the executive order to reduce the prices of prescription drugs in the US, once implemented, will have limited near-term impact on the Indian pharma companies, but it may have a bearing on their long-term capital allocation strategies. According to media reports, on 12 May 2025, the US President declared that he would be signing an executive order that would reduce the prices of prescription drug and pharmaceutical products' prices by 30 per cent to 80 per cent. Additionally, the executive order would establish a Most Favoured Nation Policy whereby the US would pay the same price as the country that pays the lowest price anywhere in the world. Jubilant Pharmova said the large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US government. Therefore, the company is starting to see excellent traction in the Contract Development and Manufacturing Organization (CDMO) Sterile Injectable business for new lines in the Spokane facility. The company expects to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier. Among individual stocks, GSK Pharma soared 8 per cent to ₹ 3,012.20 in intra-day trade. The management said the company remains committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, GSK Pharma will continue to focus on its innovative portfolio through the launch of oncology assets. The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer. In January to March 2025 quarter (Q4FY25), Torrent Pharma's domestic business continued to post strong double-digit growth despite the slowdown in the overall market. Growth in the US business has started to show signs of a pickup. Meanwhile, the management of Gland Pharma named a few additional growth drivers for the medium term. These include complex injectables for the US market, biosimilar CDMO business in India and GLP-1 CDMO in Cenexi. The company has already entered into agreements with Dr Reddy's Labs in India and another pharma company in China for biosimilar CDMO.
Business Standard
21-05-2025
- Business
- Business Standard
Market near day's high; pharma shares surge over 1%
The key equity indices traded with significant gains in morning trade, driven by strong buying interest among traders. The Nifty traded above the 24,900 level. Investors remain focused on global cues and Q4 earnings announcements. Pharma stocks saw a rebound, advancing after losses in the previous session. At 10:25 IST, the barometer index, the S&P BSE Sensex added 727.30 points or 0.90% to 81,914.51. The Nifty 50 index rallied 224.75 points or 0.91% to 24,911.75. In the broader market, the S&P BSE Mid-Cap index added 0.90% and the S&P BSE Small-Cap index jumped 0.74%. The market breadth was strong. On the BSE, 2,325 shares rose and 1,137 shares fell. A total of 199 shares were unchanged. Economy: India's infrastructure output, which tracks activity across eight sectors and makes up 40% of the country's industrial production, grew at 0.5% annually in April as against 4.6% in March, data from Ministry of Commerce & Industry showed on Tuesday. The Index of eight Core Industries is the measure of combined and individual performance of production of eight core industries: Coal, Crude Oil, Natural Gas, Refinery Products, Fertilizers, Steel, Cement and Electricity. India's retail inflation for farm as well as rural workers eased marginally to 3.48% and 3.53%, respectively, in April this year compared to the pace of price hikes for the two categories at 3.73% and 3.86% recorded in March. The All-India Consumer Price Index for Agricultural Labourers (CPI-AL) and Rural Labourers (CPI-RL) increased by 1 point each in April 2025 to stand at 1307 and 1320 points, respectively. The CPI-AL and CPI-RL were 1306 points and 1319 points, respectively, in March. Result Today: IndusInd Bank (down1.16%), Oil & Natural Gas Corporation (ONGC) (up 0.32%), Astral (down 0.60%), Colgate Palmolive (India) (up 1.08%), H.G. Infra Engineering (up 0 .48%), InterGlobe Aviation(up 0.30%), Ircon International (up 1.30%), Mankind Pharma (down 0.01% ), National Aluminium Co (up 1.09%), NTPC Green Energy (down 0.05% ), Oil India (up 0.87%), Power Finance Corp (up 0.84% ), Rail Vikas Nigam (up 0.31% ), Trident (down 0.54% ), VRL Logistics (up 1.35% ) will declare their results later today. Buzzing Index: The Nifty Pharma index advanced 1.80% to 21,842.85. The index fell 1.31% in the past trading session. Gland Pharma (up 3.66%), Torrent Pharmaceuticals (up 3.18%), Ajanta Pharma (up 2.33%), Alkem Laboratories (up 2.08%), Divis Laboratories (up 1.99%), Granules India (up 1.96%), Natco Pharma (up 1.85%), Aurobindo Pharma (up 1.79%), Lupin (up 1.76%) and Sun Pharmaceutical Industries (up 1.73%) surged. Gland Pharma rallied 3.66%. The companys consolidated net profit declined 3.1% to Rs 186.54 crore in Q4 FY25, compared with Rs 192.42 crore in Q4 FY24. Revenue from operations fell 7.3% YoY to Rs 1,424.91 crore in Q4 FY25. Stocks in Spotlight: Aster DM Healthcare fell 3.24%. The company reported consolidated net profit of Rs 79.02 crore in Q4 FY25 compared with net loss of Rs 24.03 crore in Q4 from operations increased 2.7% YoY to Rs 1,000.34 crore during the quarter ended 31st March 2025. J kumar Infraprojects declined 1.42%. The companys consolidated net profit rose 12.1% to Rs 114.20 crore on 14.6% jump in revenue from operations to Rs 1,632.74 crore in Q4 FY25 over Q4 FY24.
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Gland Pharma stock volatile after announcing Q4 results, dividend; Details
Gland Pharma share price slipped 2 per cent in the morning deals, however, its losses reversed and the stock was trading 4.9 per cent higher on BSE. The volatility in the stock came after the company reported its Q4 results. At 9:55 AM, Gland Pharma shares were up 4.14 per cent at ₹1,558 per share on the BSE. In comparison, the BSE Sensex was up 0.66 per cent at 81,721.26. The market capitalisation of the company stood at ₹25,669.05 crore. The 52-week high of the stock was at ₹2,220.95 per share and the 52-week low of the stock was at ₹1,200 per share. Gland Pharma Q4 results 2025 The company announced its fourth quarter (Q4FY25) results on May 20, 2025, after market hours. The company's consolidated net profit after tax (PAT) stood at ₹186.5 crore as compared to ₹192.4crore a year ago, down 3 per cent year-on-year (Y-o-Y). Its revenue from operations also slipped 7 per cent at ₹1,424.9 crore for Q4 against ₹1,537.5 crore a year ago. Its Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹347.5 crore as compared to ₹358.7 crore a year ago. The Ebitda margin for the quarter came in at 24 per cent against 23 per cent Y-o-Y. According to the filing, research and development (R&D) expenses were ₹50.3 crore in Q4 FY25, representing 4.9 per cent of revenue, while for FY25 were ₹192.2 crore (4.7 per cent of revenue). The company launched four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), which were launched in Q4 FY25, contributing to 31 cumulative launches in FY25. In the quarter under review, five Abbreviated New Drug Application (ANDAs) were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the US (318 approved, 53 pending). NHPC Q4 results | Fortis Healthcare Q4 profit drops 7% Gland Pharma dividend The board of Gland Pharma recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. About Gland Pharma Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets.
Business Standard
21-05-2025
- Business
- Business Standard
Gland Pharma consolidated net profit declines 3.06% in the March 2025 quarter
Sales decline 7.32% to Rs 1424.91 crore Net profit of Gland Pharma declined 3.06% to Rs 186.54 crore in the quarter ended March 2025 as against Rs 192.42 crore during the previous quarter ended March 2024. Sales declined 7.32% to Rs 1424.91 crore in the quarter ended March 2025 as against Rs 1537.45 crore during the previous quarter ended March 2024. For the full year,net profit declined 9.57% to Rs 698.53 crore in the year ended March 2025 as against Rs 772.46 crore during the previous year ended March 2024. Sales declined 0.85% to Rs 5616.50 crore in the year ended March 2025 as against Rs 5664.72 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1424.911537.45 -7 5616.505664.72 -1 OPM % 24.3923.33 - 22.5923.53 - PBDT 384.09390.84 -2 1440.531477.11 -2 PBT 288.33298.23 -3 1062.661132.54 -6 NP 186.54192.42 -3 698.53772.46 -10
